Program
zinlirvimab
Its studies are mostly in HIV Infections, led by Gilead Sciences.
Furthest: phase 3, since Jun 26, 20264 company-led studies, 3 open or runningNext primary completion: Mar 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 43 open or running | phase 3since Jun 26, 2026 | Mar 19, 2021 | Mar 2029phase 3 · NCT07682961 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2021First study: phase 1 study in HIV-1 InfectionFirst studyNCT04811040 · 32 enrolled · United States
- Feb 6, 2023Phase 2 study in HIV-1 InfectionNCT05729568 · 83 enrolled · United States, Australia, Canada and more
- Jun 26, 20262 phase 3 studiesPhase 3 reachedNCT07683000, NCT07682961
Ahead
- Mar 2029Primary completion: phase 3 study in HIV-1-infectionNCT07683000
- Mar 2029Primary completion: phase 3 study in HIV InfectionsNCT07682961
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Envelope protein inhibitor”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07683000HIV-1-infection · United States | 3 | Recruiting | Mar 2029 | 590 |
| NCT07682961HIV Infections · United States, Australia, Japan | 3 | Recruiting | Mar 2029 | 590 |
| NCT05729568HIV-1 Infection · United States, Australia, Canada and more | 2 | Active, not recruiting | Jul 2, 2024 | 83 |
| NCT04811040HIV-1 Infection · United States | 1 | Completed | Jun 9, 2022 | 32 |
How it is read
Names in the registry
- “Zinlirvimab”, 4 entries
Conditions, from the studies’ own filings
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.